AcquisitionBNTX announced an all-stock acquisition offer for CVAC for ~$1.25B, with CVAC shares exchanged for $5.46 in BNTX ADS – a ~55% premium to CVAC’s trailing 3-month average price.
Financial PerformanceThe company has €438.3 million in cash and equivalents, expected to fund operations into 2028, providing a strong financial foundation.
Intellectual PropertyCureVac obtained a positive ruling from the European Patent Office that upheld the validity of a European patent.